FDA WARNING_LETTER - cheaptrustedpharmacy.com

On July 29, 2025, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to cheaptrustedpharmacy.com, citing its unlawful sale of unapproved and misbranded drugs to U.S. consumers through its website. The FDA’s review identified that the company introduces drugs into interstate commerce without proper regulatory authorization, violating sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act, which pertain to the sale of unapproved and misbranded products.

The main violations include offering drugs that are subject to specialized safety programs (Risk Evaluation and Mitigation Strategies), opioids, semaglutide, injectable products, and medications for serious conditions such as HIV/AIDS or cancer. Specific examples highlighted are “Evermide 10 (Lenalidomide),” “Inbec (Abacavir/Dolutegravir/Lamivudine),” and various injectable semaglutide products (e.g., “Semaglutide 0.5mg,” “Semanize 4 Mg”). These products are considered unapproved new drugs due to the absence of established safety and effectiveness for their intended uses, and they lack FDA approval.

The FDA underscored the significant public health risks associated with purchasing such products, including potential contamination, counterfeiting, and inaccurate active ingredient amounts. Injectable drugs pose an elevated risk by bypassing the body’s natural defenses. The agency requires cheaptrustedpharmacy.com to immediately cease offering all unapproved and misbranded drugs for sale to U.S. consumers to protect public health.